arrow_back Trending Legislation
Share share

Drug Ad Restrictions: 3-Year Ban for New Medications

This bill prohibits direct-to-consumer advertising (including on social media) of drugs for the first three years after their approval. The Secretary may waive this prohibition during the third year if the advertising would have an affirmative value to public health. After this period, the Secretary may prohibit advertising if the drug has significant adverse health effects based on studies or reports.
Key points
New drugs cannot be advertised directly to consumers for the first 3 years after approval.
The Secretary may waive the ban in the third year if the advertising has value to public health.
The Secretary may prohibit advertising after the 3-year period if the drug shows significant adverse health effects.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Responsibility in Drug Advertising Act of 2024
Print number: S 4785
Sponsor: Sen. King, Angus S., Jr. [I-ME]
Process start date: 2024-07-25
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-3-pro-preview
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Drug Ad Restrictions: 3-Year Ban for New Medications

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 4785.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2024-07-25.

What are the main provisions?

Key points include:

  • New drugs cannot be advertised directly to consumers for the first 3 years after approval.
  • The Secretary may waive the ban in the third year if the advertising has value to public health.
  • The Secretary may prohibit advertising after the 3-year period if the drug shows significant adverse health effects.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. King, Angus S., Jr. [I-ME].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-30.

Analysis and Potential Impact of S 4785

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health